Treatment of Older Patients With Newly Diagnosed AML Unfit for Traditional Therapy

Kantarjian, 2006, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome, Cancer, 106, 1090, 10.1002/cncr.21723 Appelbaum, 2006, Age and acute myeloid leukemia, Blood, 107, 3481, 10.1182/blood-2005-09-3724 Sorror, 2007, Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences, Blood, 110, 4606, 10.1182/blood-2007-06-096966 Wheatley, 2009, Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials, Br J Haematol, 145, 598, 10.1111/j.1365-2141.2009.07663.x Krug, 2010, Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes, Lancet, 376, 2000, 10.1016/S0140-6736(10)62105-8 Burnett, 2009, The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial, Br J Haematol, 145, 318, 10.1111/j.1365-2141.2009.07604.x Burnett, 2007, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment, Cancer, 109, 1114, 10.1002/cncr.22496 Fenaux, 2010, Azacytidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J Clin Oncol, 28, 562, 10.1200/JCO.2009.23.8329 Dombret, 2015, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood, 126, 291, 10.1182/blood-2015-01-621664 Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J Clin Oncol, 30, 2670, 10.1200/JCO.2011.38.9429 Hills, 2011, Applicability of a “Pick a Winner” trial design to acute myeloid leukemia, Blood, 118, 2389, 10.1182/blood-2011-02-337261 Burnett, 2012, The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML, Br J Haematol, 158, 519, 10.1111/j.1365-2141.2012.09165.x Burnett, 2011, The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome, Leukemia, 25, 1122, 10.1038/leu.2011.59 Burnett, 2015, A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia, Leukemia, 29, 1312, 10.1038/leu.2015.38 Dennis, 2015, Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia, Blood, 125, 2923, 10.1182/blood-2014-10-608117 Burnett, 2013, The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison, Leukemia, 27, 75, 10.1038/leu.2012.229 Burnett, 2013, Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival, Blood, 122, 1384, 10.1182/blood-2013-04-496596 Döhner, 2014, Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy, Blood, 124, 1426, 10.1182/blood-2014-03-560557 Garcia-Manero, 2015, Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML), Blood, 126, 453, 10.1182/blood.V126.23.453.453 Swords, 2018, Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML, Blood, 131, 1415, 10.1182/blood-2017-09-805895 DiNardo, 2018, Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study, Lancet Oncol, 19, 216, 10.1016/S1470-2045(18)30010-X Wei, 2016, Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥65 years with acute myeloid leukemia, Blood, 128, 102, 10.1182/blood.V128.22.102.102